[1] Yang Wei, Yang Huasheng, Supervisor: Jiang Liangduo,.An Analysis of Exterior - Relieving Therapy Application in the Treatment of Covid -19 [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2020, (06): 4-9,25. [doi: 10.13424/j.cnki.jsctcm.2020.06.002]
An Analysis of Exterior - Relieving Therapy Application in the Treatment of Covid -19
- Article number:
- 2096-1340(2020)06-0004-07
- Keywords:
- Covid -19; exterior - relieving syndrome; sweating therapy; Guizhi Decoction; double solution of exterior and interior
- ZTFLH:
- R256.1
- Code:
- A
- Abstract:
- Based on TCM clinical practice in the treatment of Covid - 19, this paper proposes that this disease is mainly characterized by Wei and Qi phase syndrome. Accordingly, the main effective treatment in an early stage is to disperse lung qi and dispel pathogenic factors, relieving the external symptoms. The exterior - relieving therapy can be classified into several kinds which include medicine of pungent and cool property, medicine of pungent and warm quality, medicine which can strengthen body to resolve the exterior evils, medicine which can dispel the exterior and interior evils as well as the medicine which can remove dampness to relieve exterior evils etc. . Accurate syndrome differentiation and flexible modification are necessary in the treatment of Covid -19. Attention should be paid to details and contraindications of decoction. Additionally, this paper proposes that Guizhi Decoction can be used as a trial treatment when syndrome differentiation is not obvious. The TCM treatment of Covid -19 is mainly to disperse lung qi and disperse pathogenic factors, which should be used to invigorate lung and penetrate pathogens as early as possible. It can not only improve the cure rate but also prevent the depression of positive deficiency caused by pathogenic factors , reducing the occurrence of critical illness.
References:
[1] Liu J, Liu Y, Xiang P, et al. Neutrophil - to – lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage[ EB/ OL] . ( 2020 - 02 - 12)[ 202002 - 26] . https: / / www. medrxiv. org/ content/10. 1101/ 2020. 02. 10. 20021584v1.
[2] Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome - related coronavirus: the species and its viruses— a statement of the Coronavirus Study Group[ EB/ OL] . ( 2020 - 02 - 11) [ 2020 - 02 - 26] . https: / / www. biorxiv. org/ content/10. 1101/2020. 02.07. 937862v1.
[3] Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS -CoV, MERSCoV, and 2019 - nCoV[ J/ OL] . J Med Virol,2020( 202002 - 13) [ 2020 - 02 - 26] . https: / / onlinelibrary. wiley. com/ doi/ full/10. 1002/ jmv. 25709.
[4] Steimer DA, Hernandez O, Mason DP, et al. Timing of ECMO initiation impacts survival in influenza – associated ARDS[ J] . Thorac Cardiovasc Surg, 2019, 67 ( 3) : 212-215.
[5]金寿山.金寿山温病学讲稿[M].北京:人民卫生出版社,2008.
[6]杨华升,李丽,勾春燕,等.北京地区新型冠状病毒肺炎中医证候及病机特点初探.[J].北京中医药,(2020-02-13).http://kns.cnki.net/kcms/detail/11.5635.r.20200212.2218.002.html.
[7]国家卫生健康委员会.关于印发新型冠状病毒感染的肺炎诊疗方案(试行第七版)的通知[EB/OL].(2020-03-03)[2020-03-03].http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67.shtml.
[8]周玉平,朱传新,万禧伟,等.咸宁地区3886例发热?咳嗽患者临床特征与实验室检查结果分析[J].检验医学与临床,(2020-03-04)http://kns.cnki.net/kcms/detail/50.1167.R.20200304.1246.002.html.
[9]刘媛,胡秋红,黄柏学,等.从伏气温病探讨新型冠状病毒肺炎的“有病无症”[J].中医学报,(2020-03-03)http://kns.cnki.net/kcms/detail/41.1411.R.20200302.1833.008.html.
Memo
基金项目:国家科技重大专项(2017ZX10305501);中医药防治2019-nCoV研究项目(2020YFC841500);国家中医药管理局第四批全国中医优秀人才研修项目(国中医药办人教函[2017]24)
作者简介:杨华升,博士,主任医师?E-mail:yangdoctor2000@qq.com